Company news

Acumen Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

May 13, 2024

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

May 7, 2024

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

May 6, 2024

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease

April 3, 2024

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

March 25, 2024

Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting

March 20, 2024

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

March 18, 2024

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

February 20, 2024

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

January 31, 2024

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

November 12, 2023

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

November 12, 2023

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

November 5, 2023

Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights

August 7, 2023

Acumen Announces Pricing of Upsized $130 Million Public Offering

July 17, 2023

Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock

July 16, 2023

Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023

July 15, 2023

Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights

May 8, 2023

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023

May 1, 2023

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights

March 26, 2023

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023

March 19, 2023

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease

February 12, 2023

Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors

January 3, 2023

Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights

November 13, 2022

Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022

November 6, 2022

Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease

October 23, 2022

Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights

August 14, 2022

Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022

August 7, 2022

Acumen Pharmaceuticals Reports Financial Results for First Quarter 2022 and Business Highlights

May 15, 2022

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2021 and Business Highlights

March 27, 2022

Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022

March 15, 2022

Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights

November 14, 2021

Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic Aβ Oligomers for the Treatment of Early Alzheimer’s Disease

October 6, 2021

Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering

June 29, 2021

← Newer news releases

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 45 decks. Every deck is listed under its year.